Wuxi Heyu Biomedical Technology

Abbisko Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company leverages its proprietary drug discovery platform, which integrates structure-based drug design and fragment-based drug discovery, to target previously undruggable or poorly addressed pathways in cancer. Its lead program, pimicotinib (ABSK021), is a highly selective CSF-1R inhibitor currently in Phase 3 clinical trials for the treatment of tenosynovial giant cell tumors. Headquartered in Shanghai with significant R&D operations in Wuxi, Abbisko has established strategic partnerships with global pharmaceutical leaders such as Eli Lilly and Merck KGaA. The company is listed on the Hong Kong Stock Exchange and maintains a robust pipeline of precision oncology assets focused on FGFR, EGFR, and KRAS signaling pathways.